The findings highlight the broad metabolic benefits and strong clinically meaningful efficacy of setmelanotide in this population, supporting its potential as a therapeutic option for patients with aHO and suggest reductions in visceral fat burden, hepatic steatosis, and overall cardiometabolic risk.
H. V. van Santen, S. Phillips, J. Hamilton et al.· European Journal of Endocrin...· 0 citations
In the largest randomised, placebo-controlled trial in aHO to date, setmelanotide demonstrated significant effects over placebo in the primary and key secondary efficacy endpoints at 52 weeks, with no new safety signals.
S. Phillips, H. V. van Santen, J. Hamilton et al.· European Journal of Endocrin...· 0 citations
Setmelanotide led to significantly greater reductions in BMI and hunger than placebo at 52 weeks among participants 4 to 66 years of age with acquired hypothalamic obesity.
J. Miller, H. V. van Santen, Susan A. Phillips et al.· New England Journal of Medic...· 6 citations· ⚡2
This study is the first to report CCDC149 variants in association with Congenital Hypopituitarism, supporting the possibility of impaired ciliary function as an underlying mechanism in this complex disorder.
L. Gregory, Shoshana Rath, Hanna Mandel et al.· European Journal of Endocrin...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.